Jake R. Morgan

Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population

Jake R. Morgan, Bruce R. Schackman, Jared A. Leff et al. · Journal of Substance Abuse Treatment · 2017 · 325 citations · Full text

Substance Use Disorders, Oral Naltrexone, Substance Abuse +15

Estimated Prevalence of Opioid Use Disorder in Massachusetts, 2011–2015: A Capture–Recapture Analysis

Joshua A. Barocas, Laura F. White, Jianing Wang et al. · American Journal of Public Health · 2018 · 161 citations · Full text

Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort

Jake R. Morgan, Bruce R. Schackman, Zoe Weinstein et al. · Drug and Alcohol Dependence · 2019 · 152 citations · Full text

The Cost-Effectiveness of Sofosbuvir-Based Regimens for Treatment of Hepatitis C Virus Genotype 2 or 3 Infection

Benjamin P. Linas, Devra M. Barter, Jake R. Morgan et al. · Annals of Internal Medicine · 2015 · 107 citations · Full text

Projected Estimates of Opioid Mortality After Community-Level Interventions

Benjamin P. Linas, Alexandra Savinkina, R. W. M. A. Madushani et al. · JAMA Network Open · 2021 · 71 citations · Full text